Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Kammertoens

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
European Journal of Immunology|July 28, 2009
Making and circumventing tolerance to cancerThomas Kammertoens, Thomas Blankenstein
Cancer Cell|April 20, 2013
It's the peptide-MHC affinity, stupidThomas Kammertoens, Thomas Blankenstein
Trends in Molecular Medicine|May 11, 2005
Immunotherapy: target the stroma to hit the tumorThomas Kammertoens, Thomas Schüler, Thomas Blankenstein
EMBO Molecular Medicine|January 10, 2020
"Designer cytokines" targeting the tumor vasculature-think global and act localThomas Kammertoens, Josephine Kemna, Matthias Leisegang
The Journal of Clinical Investigation|January 26, 2016
Targeting human melanoma neoantigens by T cell receptor gene therapyMatthias Leisegang, Thomas Kammertoens, Wolfgang Uckert, et al.
International Journal of Cancer|February 9, 2005
Tumor-induced antibodies resemble the response to tissue damageSusanne Preiss, Thomas Kammertoens, Christoph Lampert, et al.
International Journal of Cancer|January 4, 2012
B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF-α, perforin)Thomas Kammertoens, Zhihai Qin, Dana Briesemeister, et al.
Animals : an Open Access Journal From MDPI|July 2, 2021
Breeding and Maintenance of Immunodeficient Mouse Lines under SPF Conditions-A Call for Individualized Severity Analyses and Approval ProceduresThomas Kammertoens, Sarah Jeuthe, Heike Baranzke, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 21, 2007
Cross-talk between T cells and innate immune cells is crucial for IFN-gamma-dependent tumor rejectionZhiguang Li, Felicia Pradera, Thomas Kammertoens, et al.
Cancer Research|March 30, 2013
Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogensJinhua Zhang, Lin Chen, Xiaoman Liu, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
European Journal of Immunology|July 28, 2009
Making and circumventing tolerance to cancerThomas Kammertoens, Thomas Blankenstein
Cancer Cell|April 20, 2013
It's the peptide-MHC affinity, stupidThomas Kammertoens, Thomas Blankenstein
Trends in Molecular Medicine|May 11, 2005
Immunotherapy: target the stroma to hit the tumorThomas Kammertoens, Thomas Schüler, Thomas Blankenstein
EMBO Molecular Medicine|January 10, 2020
"Designer cytokines" targeting the tumor vasculature-think global and act localThomas Kammertoens, Josephine Kemna, Matthias Leisegang
The Journal of Clinical Investigation|January 26, 2016
Targeting human melanoma neoantigens by T cell receptor gene therapyMatthias Leisegang, Thomas Kammertoens, Wolfgang Uckert, et al.
International Journal of Cancer|February 9, 2005
Tumor-induced antibodies resemble the response to tissue damageSusanne Preiss, Thomas Kammertoens, Christoph Lampert, et al.
International Journal of Cancer|January 4, 2012
B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF-α, perforin)Thomas Kammertoens, Zhihai Qin, Dana Briesemeister, et al.
Animals : an Open Access Journal From MDPI|July 2, 2021
Breeding and Maintenance of Immunodeficient Mouse Lines under SPF Conditions-A Call for Individualized Severity Analyses and Approval ProceduresThomas Kammertoens, Sarah Jeuthe, Heike Baranzke, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 21, 2007
Cross-talk between T cells and innate immune cells is crucial for IFN-gamma-dependent tumor rejectionZhiguang Li, Felicia Pradera, Thomas Kammertoens, et al.
Cancer Research|March 30, 2013
Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogensJinhua Zhang, Lin Chen, Xiaoman Liu, et al.
Pageof 4